Abstract Mutations in coding and non-coding regions of FUS cause amyotrophic lateral sclerosis (ALS). The latter mutations may exert toxicity by increasing FUS accumulation. We show here that broad expression within the nervous system of wild-type or either of two ALS-linked mutants of human FUS in mice produces progressive motor phenotypes accompanied by characteristic ALSlike pathology. FUS levels are autoregulated by a mechanism in which human FUS downregulates endogenous FUS at mRNA and protein levels. Increasing wild-type human FUS expression achieved by saturating this autoregulatory mechanism produces a rapidly progressive phenotype and dosedependent lethality. Transcriptome analysis reveals mis-regulation of genes that are largely not observed upon FUS reduction. Likely mechanisms for FUS neurotoxicity include autophagy inhibition and defective RNA metabolism. Thus, our results reveal that overriding FUS autoregulation will trigger gain-of-function toxicity via altered autophagy-lysosome pathway and RNA metabolism function, highlighting a role for protein and RNA dyshomeostasis in FUSmediated toxicity.
Introduction
Two seemingly different adult-onset neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD), share overlapping clinical and pathological characteristics (reviewed in Ling et al., 2013; Robberecht and Philips, 2013; Gao et al., 2017) . The landmark discovery of TAR-DNA binding protein (TDP-43) as a major component of ubiquitinated aggregates in ALS and FTLD (frontotemporal lobar degeneration, a term used to stress the pathological classification of FTD) patients (Neumann et al., 2006; Arai et al., 2006) led to the identification of ALS and FTD-causing mutations in the genes encoding two nucleic acid-binding proteins, TDP-43 (Sreedharan et al., 2008; Kabashi et al., 2008; Van Deerlin et al., 2008) and fused in sarcoma/ translocated in liposarcoma (FUS/TLS) (hereafter referred to as FUS) (Kwiatkowski et al., 2009; Vance et al., 2009 ). In the past decade, mutations in several additional genes, including GGGGCC hexanucleotide-repeat expansion in the C9ORF72 gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012) and point mutations in UBQLN2 , VCP , CHMP2B (Momeni et al., 2006; Parkinson et al., 2006) , and TBK1 (Cirulli et al., 2015; Freischmidt et al., 2015; Pottier et al., 2015) were also identified as genetic causes for both ALS and FTD. These genetic discoveries, coupled with pathological inclusions of TDP-43 (Neumann et al., 2006; Arai et al., 2006) or FUS (Neumann et al., 2009 ) that are found both in ALS and FTD, have supported common molecular mechanisms, in particular, disruption in RNA and protein homeostasis, to underlie both diseases (reviewed in Ling et al., 2013; Lattante et al., 2015; Taylor et al., 2016) .
Molecularly, FUS is a 526 amino acid protein containing a prion-like low-complexity domain (Kato et al., 2012; Cushman et al., 2010) , followed by a nuclear export signal, a RNA recognition motif (RRM) domain, arginine/glycine (R/G)-rich domains, a zinc-finger motif and nuclear localization signal. FUS binds to single-and double-stranded DNA as well as RNA and participates in multiple cellular functions Tan and Manley, 2009; Lagier-Tourenne et al., 2010; Schwartz et al., 2015; Ling, 2018) , in particular in transcription-splicing coupling (LagierTourenne et al., 2012; Yu and Reed, 2015) , alternative splicing and polyadenylation (LagierTourenne et al., 2012; Ishigaki et al., 2012; Rogelj et al., 2012; Sun et al., 2015; Masuda et al., 2015; Reber et al., 2016) , and the localization and translation of RNA (Kanai et al., 2004; Fujii and Takumi, 2005; Yasuda et al., 2013) . A preponderance of the ALS/FTD causing mutations (48 out of 60) is clustered in the FUS extreme C-terminus that contains its non-canonical nuclear localization signal (known as PY-NLS) (Dormann et al., 2010; Lattante et al., 2013) . Correspondingly, such FUS mutants have been shown to result in increased cytosolic accumulation which correlates with disease severity (Dormann et al., 2010; Bosco et al., 2010; Gal et al., 2011; Vance et al., 2013) . Neuronal cytoplasmic inclusions of FUS are found in ALS patients with mutations in FUS (Kwiatkowski et al., 2009; Vance et al., 2009; Dormann et al., 2010) , suggesting that (i) disturbing the nuclear-cytosolic distribution can lead to FUS proteinopathy, and (ii) loss of nuclear RNA processing functions may contribute to ALS pathogenesis. Intriguingly, mutations in the 3'-UTR of FUS leading to elevated FUS accumulation are known to be causal for ALS (Sabatelli et al., 2013) . This is reminiscent of increased copy number of the APP gene (which encodes amyloid precursor protein and is causal for Alzheimer's disease [Sleegers et al., 2006] ) and of the SNCA gene (which encodes a-synuclein and is causal for Parkinson's disease [Singleton et al., 2003] ). Therefore, the evidence suggests elevated expression levels of genes encoding these pathological hallmarks are sufficient to drive neurodegeneration.
The pathological hallmark of FUS inclusions in ALS and FTD is characterized by the loss of nuclear FUS immunoreactivity with concomitant cytosolic accumulation, suggesting that both loss of nuclear FUS function and gain of additional toxic properties may be involved. However, Kino and colleagues used outbred FUS knockout mice to show that these FUS knockout mice do not develop ALS disease phenotypes (Kino et al., 2015) . In contrast, mice expressing disease-causing FUS mutations or FUS with NLS-deletions developed motor neuron degeneration, favoring a 'gain-of-toxic properties' model (Scekic-Zahirovic et al., 2016; Sharma et al., 2016; Shiihashi et al., 2016; Devoy et al., 2017; Ló pez-Erauskin et al., 2018) . Indeed, ALS-linked mutations in FUS have been suggested to affect diverse functions, including gain and loss of RNA processing Reber et al., 2016) , deregulation of SMN function Yamazaki et al., 2012; Groen et al., 2013; Tsuiji et al., 2013) , biogenesis of circular RNA (Errichelli et al., 2017) , DNA damage response (Qiu et al., 2014; Wang et al., 2013) , axonal transport (Groen et al., 2013; Guo et al., 2017) , activity-dependent translation (Sephton et al., 2014) , and intra axonal protein synthesis (Ló pezErauskin et al., 2018) . Although all of these defects may contribute to ALS and FTD pathogenesis, how any of these proposed dysfunctions contributes to neurodegeneration remains to be determined.
Autophagy, a tightly regulated catabolic process, degrades long-lived proteins, membrane proteins, and organelles via the lysosome (Mizushima and Komatsu, 2011; Shen and Mizushima, 2014) . Not surprisingly, autophagy dysfunction has been implicated in various neurodegenerative diseases, including ALS (Wong and Cuervo, 2010; Nixon and Yang, 2012) . The notion that autophagy dysfunction contributes to ALS-FTD pathogenesis is strongly supported by the identification of numerous ALS-FTD genes involved in autophagy regulation, including SQSTM1 , OPTN (Maruyama et al., 2010; Wong and Holzbaur, 2014) , TBK1 (Cirulli et al., 2015; Freischmidt et al., 2015; Pottier et al., 2015) , and VCP . Intriguingly, recent work has shown that loss of TDP-43 inhibits autophagy by blocking the fusion of autophagosomes with lysosomes (Xia et al., 2016) , and that enhancing autophagy may be beneficial for mice modeling TDP-43 proteinopathies (Wang et al., 2012) . Stress granules are cleared by autophagy (Buchan et al., 2013) , further supporting the link between RNA-containing ribonucleoprotein complexes and autophagy.
Here we report that widespread expression of wild type FUS or ALS-linked mutations (R514G and R521C) in FUS within the central nervous system of mice can cause progressive motor deficits accompanied by ALS-like lower motor neuron pathology. An increase in expression of wild type FUS sharply accelerates disease phenotype and triggers early mortality accompanied by disturbances in both protein homeostasis and RNA processing, likely by saturating FUS autoregulation. Furthermore, we report that increased expression of wild type or disease-linked mutant FUS inhibits autophagy, suggestive of a potential gain-of-function proteotoxicity stress mechanism contributing to FUS-mediated neurodegeneration.
Results
Generation of 'floxed' FUS transgenic mice with broad expression in the central nervous system Transgenic mice were produced to express either wild-type or either of two ALS-linked mutant human FUS broadly throughout the central nervous system (CNS) using the murine prion promoter (Arnold et al., 2013 ) previously reported to drive transgene expression most abundantly in the CNS, including neurons, astrocytes and oligodendrocytes (see below). cDNAs for human wild type (hereafter referred as FUS WT ) and either of two ALS-linked mutants of FUS, R514G (arginine to glycine substitution at amino acid 514, hereafter referred as FUS R514G ) and R521C (arginine to cysteine substitution at amino acid 521, hereafter referred as FUS R521C ) were fused to a N-terminal hemagglutinin (HA) tag and placed under the control of the murine prion promoter ( Figure 1A ). Each transgene was flanked with loxP sites to permit deletion in the presence of Cre recombinase activity. Twelve lines were established from 34 founders (three wild type lines from seven founders, 5 R514G lines from 13 founders, and 4 R521C lines from 14 founders). The human FUS transgene (detected with an antibody to the HA-tag) was mostly confined to the CNS [with little or no expression in other tissues ( Figure 1D ,E) were selected for further characterization.
To further confirm the autoregulatory pathway at a single cell level, we exploited antibodies we have generated that are specific to either human or mouse FUS ( Figure 1F ) to distinguish either protein using confocal microscopy. Spinal cord motor neurons expressing higher levels of human FUS (cells labeled as 1, 2, 3, 4, five in Figure 1G ) had near complete elimination of mouse FUS, while the subset of neurons without detectable human FUS retained a level of mouse FUS indistinguishable from that in mouse neurons of non-transgenic animals (cells labeled as 6, 7, eight in Figure 1G ). Collectively, we conclude that an auto-regulatory mechanism regulating FUS mRNA stability or maturation to maintain FUS level within individual cells of the mouse central nervous system (CNS).
Age-dependent lower motor deficits in FUS transgenic mice
Although transgenic mice from all three genotypes appeared normal at birth and developed normal weight into adulthood, all FUS transgenic animals expressing wild type or ALS-linked mutations in which human FUS accumulated to at least half the FUS level in normal mice developed age-dependent abnormal posture, with lower stance and hunched back, an abnormal clasping response, reduced hind limb spread (upper panel of Figure 2A ), and a progressively abnormal gait (lower panel of Figure 2A ). While all genotypes displayed normal stride-length at two-months of age, shorter front and hind-limb stride-length developed by 12 months of age ( Figure 2B ) in all FUS transgenic lines.
To further examine whether the age-dependent motor deficits in the FUS transgenic mice were accompanied by neuromuscular abnormalities similar to those clinically observed in human ALS, electromyograms (EMG) were recorded from the gastrocnemius muscle in the absence of any neurogenic stimulus (in isoflurane-anesthetized animals) ( Figure 2C ). Consistent with our previous findings (Arnold et al., 2013) , high-frequency spontaneous firings of the motor units (i.e., fibrillations) were recorded in symptomatic SOD1 G93A transgenic mice that will ultimately develop fatal paralytic ALSlike disease. Similar fibrillations, albeit less frequent, were observed in all 12-month-old FUS transgenic mice, which were absent in non-transgenic littermates ( Figure 2C ), indicating widespread denervation of neuromuscular junctions (NMJs) and motor unit degeneration and regeneration. The degree of denervation of the gastrocnemius muscle was further evaluated by colocalization of markers to both presynaptic terminals and postsynaptic densities with synaptophysin and a-Bungarotoxin, respectively. While muscles were fully innervated at 2 months of age in all FUS transgenic mice, up to~30% of the NMJs were lost by 12 months of age ( Figure 2D) , consistent with the abnormalities detected by EMG. This was accompanied by an age-dependent loss of large (>8.5 mm) caliber motor axons in 12-month-old FUS WT Figure 3A) . The dose-dependent down-regulation of mouse FUS was further confirmed at the mRNA level ( Figure 3B ). While the doubly hemizygous (line 101 crossed with line 136), and homozygous (line 101) FUS WT transgenic mice appeared normal at birth, they rapidly developed neurological disease as early as 2 weeks of age, including abnormal clasping (upper panel of Figure 3C ) and abnormal gait (lower panel of Figure 3C ). A marked reduced stride length of the front and hind limbs of both doubly hemizygous and homozygous FUS WT mice was detected by 3 weeks of age ( Figure 3D ), which was accompanied by progressive worsened clasping, lowered posture and increased tremor when compared with the age-matched non-transgenic littermates and singly hemizygous FUS WT mice ( Figure 3E ). These doubly hemizygous and homozygous FUS WT mice eventually developed paralysis.
None survived beyond 40 days of age ( Figure 3F ** **** **** **** *** * * * * ** ** *** *** * * ** *** *** *** ** ** ** * **** **** **** **** **** **** **** **** **** * * * To better understand the biological processes and pathways affected by increased FUS level, these DEGs were further classified using KEGG (Kyoto Encyclopedia of Genes and Genomes) database. This analysis showed that the KEGG pathways of the most up-regulated genes are involved in lysosomes, antigen processing and presentation, cytokine-cytokine receptor interactions, the MAPK or p53 signaling pathways, and ECM-receptor interactions (Supplementary file 1c), whereas KEGG pathways of the most down-regulated genes were involved in steroid biosynthesis and terpenoid backbone biosynthesis (Supplementary file 1d). The top six most up-regulated RNAs (Ifit1, Irf7, Lcn2, Ifit3, Gbp2, and Oasl2) with a > 20 fold change and the six most down-regulated RNAs (Chodl, Ugt8a, Tesc, Serpinb1a, Btdb17 and Gjc2) were validated by RT-qPCR in both doubly hemizygous and homozygous (line 101) FUS WT spinal cords ( Figure 6C,D) . Similarly, up-regulated RNA levels of lysosomal genes (including Ctss, Lamptm5, Ctsc, Slc11a1, and Ctsh - Figure 6E ) and genes involved in the MAPK kinase pathway (Cd14, Dusp5, Flnc, Myc and Rac2 - Figure 6F ) were also confirmed by qRT-PCR in both doubly hemizygous and homozygous (line 101) FUS WT mice.
We have previously shown that genes with exceptionally long introns (>100 kb per average intron length), which encode proteins that are essential for neuronal functional and integrity, depend on both TDP-43 and FUS, with reduction in either protein reducing accumulation of the corresponding RNAs (Lagier-Tourenne et al., 2012; Polymenidou et al., 2011) . Accumulation of the RNAs from these very long genes (including Kcnip4, Nkain2, Park2, Nrxn3, Pcdh9, Grm and Hs2st3) was also reduced in both doubly hemizygous (line 101 and line 136) and homozygous (line 101) FUS WT mice ( Figure 6E ). Additionally, all four genes encoding subunits of neuronal intermediate filaments (Nefl, Nefm, Nefh, and Prph), together with the motor neuron-specific gene Chat, were down-regulated in spinal cords of doubly hemizygous and homozygous (line 101) FUS WT mice, compared to agematched non-transgenic and either hemizygous mouse lines ( Figure 6F ). Taken together, the data suggest that neurons are more susceptible to the increasing wild type human FUS levels, and increasing FUS levels by as little as 2-fold produces a counterintuitive, apparent loss of FUS function for maturation of the pre-mRNAs encoded by genes with exceptionally long introns. Of note, the majority of mRNAs showed comparable expression levels with those of control mice, when qRT-PCR were performed for the P14 mice ( Figure 6-figure supplement 3) . At this age, the mice overexpressing FUS showed no apparent phenotype (Figure 3) , suggesting that the massive transcription changes at late stage are dominated by the effects of neurodegeneration. Therefore, FUS over-expression does not induce widespread transcription changes at P14, but does lead to toxicity, and at late stages, this involves alterations in RNA metabolism ( Figure 6E ) and autophagy (see below). Transcriptome perturbations from FUS overexpression are distinct from endogenous FUS knockdown Because of the autoregulatory mechanism for FUS expression, the drastic expression changes observed in the both doubly hemizygous and homozygous (line 101) FUS WT mice may be due to the reduction of endogenous mouse FUS protein, or the over-expression of functional human wild-type FUS protein, or both ( Figures 1, 3 and 7A). To determine whether the expression changes were primarily caused by the loss of endogenous FUS function and/or the dose-increased levels of FUS leading to gain-of-toxicity(ies), we compared the transcriptomic changes found in our 30 day old homozygous overexpressing FUS WT mice (OE) with those reported in mice with reduced FUS levels upon anti-sense oligonucleotide (ASO)-mediated knock-down (KD) (Lagier-Tourenne et al., 2012) . In addition to the qualitative separation and clustering of the various groups observed in the PCA and clustered heatmaps ( Figure 7B-D) , we tested the divergence of transcriptome changes from wild type in both overexpression and knockdown models. We make the following assumption: to the extent that the observed phenotype in the overexpression samples stems primarily from the loss of endogenous FUS, transcriptome changes in both models should be reflected in a shared set of genes, with shared direction of expression changes. Conversely, if the observed overexpression phenotype was the result of FUS overexpression, genes perturbed in both conditions would be expected to display expression changes in opposite directions. Differentially expressed genes are thus classified into two main categories: Similarly perturbed, in which the directions of expression change are the same in both conditions, and conversely perturbed, in which expression changes are in opposing directions. The bias of the proportional distribution of similarly and conversely perturbed genes is then used to identify the primary factor. If the distribution is opposite-dominant, with more conversely perturbed genes, FUS overexpression is likely the factor of interest, that is, the over-expression of FUS could drive the observed phenotype. If the distribution is instead similar-dominant, we infer that FUS reduction is the key factor. A schematic overview is shown in Figure 7 -figure supplement 1A.
To determine the significance of this proportional shift, we can perform a binomial test of the proportion against the null model. The null model represents a case in which the genes are not differentially expressed. As such, we expect gene fold changes to be normally distributed around a mean of 0. Thus, P(conversely perturbed)=P(similarly perturbed)=0.5, resulting in a 50-50 distribution of genes in each category. Genes passing our significance cutoff (FDR < 0.1) demonstrated a marked opposite-dominant pattern, with a conversely perturbed proportion of 0.629 ± 0.017 (95% confidence interval) ( Figure 7D ). In contrast, proportional analysis on genes above our significance cutoff showed proportions close to the Null Model, with a conversely perturbed proportion of 0.533 ± 0.014 (95% Confidence interval) (Figure 7-figure supplement 1B) . While this 'insignificant' gene set remained conversely perturbed, we note that the FDR cutoff is an arbitrary value, and that the gene set still contains genes with low p-values. This is clearly shown when the analysis is repeated across various cutoff values, in which the proportion of the 'insignificant' set approaches the Null Model (Figure 7-figure supplement 1C) . Taken together, the lower motor neuron disease associated with dose-dependent increased accumulation of human FUS WT , is primarily driven by gain-of-toxicity rather than loss of function of endogenous FUS. Based on the known FUS-binding sites (Lagier-Tourenne et al., 2012), 23% of oppositely-regulated mRNAs (conversely perturbed category: expression changes are in opposing directions in FUS over-expression and knockdown conditions, 199 out of 862 genes) and 31% of co-regulated mRNAs (similarly perturbed category: the directions of expression change are the same in both FUS overexpression and knockdown conditions, 158 out of 507 genes) are bound by FUS. In the conversely perturbed category, FUS binds to 27% and 17% of mRNAs that are either down-or up-regulated in FUS-overexpression conditions, whereas FUS binds to 31% of the down-regulated mRNAs (69 out of 222) and 31% up-regulated mRNAs (89 out of 285) in the similarly perturbed category ( Figure 7D) .
Intriguingly, unbiased gene ontology (GO) analyses of these four categories of DEGs revealed that distinct biological processes are affected in each group. In the category i OE-down/KD-up group, mitochondrial respiratory chain and ribose phosphate metabolic process are affected; in the category ii OE-down/KD-up group, stem cell population maintenance and cytokine-mediated signaling pathway; in the category iii OE down/KD down group, central nervous system myelination, and regulation of synaptic plasticity are affected; in the category iv OE up/KD up group, innate immune 
Rescue of FUS-null lethality by CNS-expression of wild type human FUS
The apparent loss of RNA processing function despite increased overall FUS levels from expression of human wild type or mutant FUS (and autoregulated reduction in mouse FUS) raised the possibility that the human FUS cannot functionally replace mouse FUS, even though there is a 95.1% homology (at protein level) between the two proteins. To rule out this possibility, we produced FUS WT mice (in a pure C57BL/6 background) in which both endogenous FUS alleles were disrupted (Hicks et al., 2000) ( Figure 8A ). While endogenous FUS-null mice in this background die shortly after birth, the FUS WT transgene complemented the essential FUS functions throughout early development albeit with lower Mendelian ratio ( Figure 8A-B) . Levels of RNAs from the long intron-containing genes, as well as the FUS-dependent up-regulated genes, lysosomal genes and MAPK pathway genes were assayed by qRT-PCR in RNAs extracted from spinal cords of aged-matched (40 day-old) prnp-FUS WT ::Fus -/-and Fus +/+ mice ( Figure 8C-D) . Most were nearly fully restored to their levels in nontransgenic mice, confirming the functional rescue of FUS function, albeit the most-down regulated genes were only partially rescued ( Figure 8C ), suggesting that maturation of these RNAs is very sensitive to FUS level. Altogether the near complete rescue of RNA expression changes in the FUS WT transgenic mice with both endogenous mouse alleles disrupted indicates that wild type human FUS protein complements the loss of the endogenous mouse FUS protein. Taken together, these genetic and genomic data suggest that even a slight imbalance of FUS level is critical for its proper function in the CNS and increasing FUS level exerts gain-of-toxic effects.
Protein homeostasis defects via inhibiting autophagy in mice expressing increased levels of wild type FUS
Upregulation of lysosomal genes in the homozygous FUS WT mice suggests changes in the status of protein homeostasis. We first examined whether the human transgenes form any aggregation. The majority of FUS was nuclear, with only a small portion in the cytosol in the neurons of homozygous FUS WT mice ( Figure 9A ). Although ubiquitin-positive aggregates were not observed (data not shown), accumulation of p62/SQSTM1 (sequestosome 1) accumulated found in the motor neurons of homozygotes FUS WT mice, but not the non-transgenic and hemizygote FUS WT mice nor neighboring non-motor neurons ( Figure 9A ), suggesting a potential autophagic deficit in these motor neurons.
To determine whether FUS regulates autophagy, we exploited a dual fluorescence mCherry-GFP-LC3 system, whose expression leads to formation of puncta upon its incorporation into autophagosomes (Mizushima et al., 2010) during nutrient deprivation media (NLM)-induced autophagy in neuronal like cells (Neuro2A) (Young et al., 2009) . As GFP fluorescence is sensitive to pH, yellow puncta (red +green) are indicative of autophagosomes (neutral pH), while red puncta mark autophagosomes that have fused with lysosomes to create autolysosomes (acidic pH) ( Figure 9B ). As expected, after 8 hr of NLM treatment of Neuro2A cells transiently expressing mCherry-GFP-LC3 and the blue fluorescence protein (BFP) as a control, robust autophagy (setting >7 puncta for autophagy activation) was induced as revealed by the accumulation of LC3 puncta in 45% of the cells ( Figure 9C,D) . However, increased expression of BFP-tagged wild-type FUS, FUS R514C , or FUS R521C almost completely inhibited nutrient deprivation driven autophagic activation ( Figure 9E-F) , with a significant reduction in the fraction of red puncta that correspond to autolysosomes and an increase in the number of autophagosomes (yellow puncta) ( Figure 9C,E) . Immunofluorescence of p62 is used as an indirect measure of the autophagic flux (Larsen et al., 2010) , as association of p62 with autophagosomes drives its degradation after fusion with autolysosomes. As anticipated, p62 puncta accumulation was reduced in Neuro2A cells expressing BFP upon NLM addition ( Figure 9C , two right top and middle panels). However, increased levels of FUS WT did not suppress the NLM-mediated p62 puncta accumulation, but rather increased the percentage of cells with p62 puncta ( Figure 9C,F) , indicative of the compromised autophagic flux pathway. These findings indicate that increased expression of wild-type or either of these ALS-linked FUS mutants inhibits autophagy.
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Discussion
Here we report the generation and characterization of transgenic mice that express wild type or either of two ALS-linked mutants of human FUS (R514G and R521C) broadly in the CNS, with transgene expression levels and patterns to that of endogenous mouse FUS. These mice developed progressive and mutant-enhanced motor deficits accompanied by ALS-like lower motor neuron pathology. Furthermore, FUS autoregulates its own protein expression level in the CNS. An increase in expression of wild type FUS can saturate this autoregulation and thereby sharply accelerates disease phenotypes and triggers early mortality accompanied by disturbances in both protein homeostasis and RNA processing ( Figure 10 ). In particular, our data reveal a role for FUS in regulating autophagy. Furthermore, increasing FUS levels could affect neuronal and synaptic functions by causing a loss of RNA processing for particularly long genes. Thus, disruption of FUS homeostasis incurs gain-of-function toxicity directed against autophagy and loss-of RNA processing function, thereby providing an explanation for how FUS can promote disease pathogenesis in the absence of mutation ( Figure 10) . FUS auto-regulation is known to maintain normal FUS levels and the underlying mechanisms have been previously described in cultured cells Dini Modigliani et al., 2014) and in a recent humanized FUS mouse model (Ló pez-Erauskin et al., 2018). One striking feature of all 7 FUS transgenic mouse lines we produced here is FUS autoregulation in the adult mouse CNS, which leads to mice with transgene levels that are close to mouse FUS in non-transgenic animals While all transgenic animals (FUS WT , FUS R514G and FUS R521C ) initially appeared normal, with typical development and weight gain into adult life, by 12 months of age wild-type and mutant FUS mice develop abnormal motor phenotypes, including clasping, lower posture and reduced hind limb spread, decreased stride-length, increased EMG activity, a reduction in the number of spinal cord motor neurons and their axons and a significant loss of hind limb neuromuscular innervation. In addition, FUS WT mice are less affected compared with FUS R514G mice, suggesting a mutant-enhanced toxicity. These abnormalities are all found in ALS pathogenesis in mutant SOD1 mouse models and patients (Bruijn et al., 2004) . Despite continued mutant accumulation, however, disease is at best very slowly progressive and does not lead to lower limb paralysis by ages up to 24 months. Furthermore, Figure 8 continued validated genes in Figure 6 showed that expression levels of genes with exceptionally long introns, motor neurons genes, lysosomal gens and MAPK pathway genes and the majority of most up-regulated genes could be rescued to the levels of non-transgenic animals. The majority of most downregulated genes were not able to be rescued, suggesting that these genes may be extremely sensitive to FUS level. although R521C mutation is one of the most frequent FUS mutations in ALS, expression of R521C in mice did not produce motor axon loss, but rather sensory axon loss, which differs from the FUSrelated ALS in human. By contrast, wild-type and R514G transgene produce both the motor and sensory axon degeneration. Thus, it is possible that the observed sensory deficits may be caused by transgene expression driven by the murine prion promoter. However, GEM bodies in the spinal cord motor neurons of FUS R521C mice were significantly reduced , an indication of reduced SMN (survival motor neuron) function. This is reminiscent of the notion that altered circuit function could underlie the neurodegeneration as in spinal muscular atrophy (SMA) (Mentis et al., 2011) , in which dysfunction of cholinergic sensory neurons and interneurons could lead to The following source data is available for figure 9:
Source data 1. Figure 10 . Proposed model of FUS-mediated neurodegeneration. FUS homeostasis is essential for maintaining both protein and RNA homeostasis. The level of FUS is maintained possibly through nonsense-mediated decay and/or miRNA-mediated mechanisms (see text for references). Elevated FUS level produces both gain-of-toxic properties by either increasing proteotoxic stress or expression of stress genes and loss-of RNA-processing function in which genes involved in long transcripts and synaptic functions are selectively affected. Together they cause neuronal and synaptic dysfunction and eventual neuronal death. DOI: https://doi.org/10.7554/eLife.40811.031 motoneuron degeneration Lotti et al., 2012) . Further studies are required to investigate the possibilities of altered motor-sensory circuit in FUS pathogenesis.
More importantly, we uncovered that the homeostatic levels of FUS are essential for proper neuron function, as a 2-fold increase in FUS levels accelerated the disease at least 5-fold (Figure 3) . Elevated expression levels of genes encoding the pathological hallmarks are not without precedent in other neurodegenerative diseases, such as duplication of the APP gene (amyloid precursor protein, causal for Alzheimer's disease) (Sleegers et al., 2006) , and locus triplication of a-synuclein (causal for Parkinson's disease) (Singleton et al., 2003) . Furthermore, ALS-causing mutations in the 3'-UTR of FUS gene leading to elevated FUS levels have been identified (Sabatelli et al., 2013) . Similar findings, that variants within the 3'-UTR of TARDBP gene can lead to increased TDP-43 expression, have also been reported for FTD (Gitcho et al., 2009) . Collectively, the evidence suggests that beside the disease-linked mutations in the coding regions, the factors leading to elevated expression of these key disease genes could contribute to disease pathogenesis.
CNS-expression of wild type human FUS rescues the FUS-null lethality in mice, suggesting that human FUS protein can functionally replace the mouse FUS gene (Ló pez-Erauskin et al., 2018). Furthermore, genome-wide expression profiling reveals gene changes that are largely distinct with FUSknockdown using antisense oligonucleotides. Indeed, work by Kino and colleagues showed that the behavior and pathological phenotypes caused by FUS deletion are largely distinct from those observed in ALS (Kino et al., 2015) , thereby supporting the notion that it is unlikely that FUS-mediated ALS is initiated by the loss-of-FUS-function. Nevertheless, varying FUS levels, that is, FUS overexpression (OE) and FUS knockdown (KD) conditions, could affect distinct and similar biological processes. For example, similar biological processes, such as synaptic functions, myelination, and immune response, can be affected by either increased or lowered levels of FUS. Conversely, FUS-OE and FUS-KD may have opposite effects on mitochondrial function. Interestingly, dysfunctions of these processes, for example, synaptic deficits (Ló pez-Erauskin et al., 2018; Sephton et al., 2014) and mitochondria damage (Deng et al., 2015) , have been proposed as potential FUS-mediated pathologies. As (i) FUS pathology is associated with loss of nuclear FUS and concomitant cytosolic FUS accumulation (Neumann et al., 2009; Dormann et al., 2010) , and (ii) the strong phenotype produced by over-expression of wild type FUS did not correlate with FUS aggregation as the majority of FUS remains in the nucleus, a likely scenario is that the toxic cascade is initiated at the nucleus with dysregulation of RNA processing being one of the potential mechanisms, and subsequently, is exacerbated by the loss of nuclear FUS.
Autophagy dysfunction has been implicated in various neurodegenerative diseases, including ALS (Wong and Cuervo, 2010; Nixon and Yang, 2012) . We showed here that increased FUS expression (wild type or disease-linked mutants) is sufficient to inhibit autophagy induction and flux using both LC3 and p62 as markers (Figure 9) . Interestingly, the majority of FUS protein remained in the nucleus of motor neurons, but not in other cells, in the spinal cord and co-localized with p62 (Figure 9) , suggesting perturbed protein homeostasis in motor neurons and that motor neurons may be more susceptible to elevated FUS levels. Furthermore, recent discoveries of many ALS-FTD genes, including SQSTM1 , OPTN (Maruyama et al., 2010; Wong and Holzbaur, 2014) , TBK1 (Cirulli et al., 2015; Freischmidt et al., 2015; Pottier et al., 2015) , and VCP , that are involved in autophagy, indicates that autophagy dysfunction plays a pivotal role in ALS-FTD pathogenesis. Further studies investigating the molecular mechanisms of how overexpression of FUS inhibits autophagy will be urgently needed.
Activation of astrocytes (astrogliosis) is one hallmark of ALS pathology (Schiffer et al., 1996) . Reactive astrocytes become apparent in lumbar spinal cord sections of in all three genotypes in aged (10~12 month-old) animals. Similar to the endogenous protein, human FUS transgenes are expressed in both neurons and astrocytes. Since pathological aggregation of FUS can be found in neurons and non-neurons, including astrocytes (Neumann et al., 2009) , the signal initiating astrogliosis could come either from motor neurons, from astrocytes, or from both. This is reminiscent of the non-cell autonomous toxicity mediated by mutant SOD1 in ALS pathogenesis (Ilieva et al., 2009 ) and can be tested in this set of transgenic mice by using tissue-specific Cre recombinasemediated excision of the transgene in neurons or astrocytes (Lobsiger et al., 2009; Yamanaka et al., 2008; Boillée et al., 2006) . However, in contrast to SOD1-mediated toxicity, it appears that neither endogenous nor transgenic FUS is expressed in microglia ( Figure 5 , see also (Qiu et al., 2014) ), suggesting that disease pathogenesis is not driven by FUS-mediated toxicity within the microglia.
In conclusion, our FUS mouse models resemble the endogenous FUS expression pattern and levels and developed age-dependent and mutant-enhanced phenotypes. We provide evidence that elevated FUS levels produce gain-of-toxic properties by overriding FUS autoregulation, disrupting protein and RNA homeostasis. These disruptions are, at least in part, due to autophagy inhibition causing proteotoxic stress and a loss of normal RNA processing function, in which genes with long transcripts and involved in synaptic function are selectively affected. Together, these abnormalities promote neural and synaptic dysfunction, culminating in neuron death. Thus, maintaining FUS homeostasis, which in turn is required for proper protein and RNA homeostasis, is essential for normal neuron function (Figure 10 ). Generation of transgenic mice expressing floxed wild type and ALSlinked mutations in FUS cDNA encoding human FUS and its ALS-linked mutations (R514G and R521C) were amplified by PCR with a N-terminal hemagglutinin (HA) tag and cloned into Xho-I site of the MoPrp.Xho plasmid (ATCC#JHU-2). Open reading frames of the resulting plasmids were sequenced and confirmed. To generate 'floxed' transgene constructs, Not-I was used to liberate the transgene fragments and subcloned into vector containing two flanking loxP sites. 'Floxed' transgene constructs were excised with Cla-I and injected into the pronuclei of fertilized eggs to generate FUS transgenic mice (in C57Bl6/C3H hybrid background). Multiple founder lines with varying expression level of the transgenes were obtained. Lines of comparable wild type or mutant human FUS accumulation were selected for subsequent analysis. Mice were backcrossed to C57Bl6 for more than five generations and used for analysis in this paper. Genotype primers used in this study are: 5'-GAG GAT TTC CCA GTG GAG GT-3' and 5'-CTC CAT CAA AGG GAC CTG AA-3'. All studies were carried out under protocols approved by the Institutional Animal Care and Use Committee of the University of California, San Diego (UCSD) and the National University of Singapore (NUS), and were in compliance with Association for Assessment of Laboratory Animal Care guidelines for animal use. All studies were performed in such a manner as to minimize group size and animal suffering. The approved NUS protocol numbers are BR17-0928 and R16-0954.
Materials and methods
RT-QPCR
Total RNA from half a mouse cortex was isolated in Trizol (Invitrogen) and prepared for reverse transcription according to manufacturer's instructions. Real time quantitative PCR was performed on 40 ng of total cDNA using the iQSYBR Green supermix (Bio-Rad) with the iCycler iQ detection system according to manufacturer's instructions. Mus musculus ribosomal protein S9 (Rps9, NM_029767) and actin gamma subunit protein (Actg1, NM_009609) genes were also measured as endogenous references across all experimental conditions.
Immunohistochemistry, motor neuron and axon quantification
Tissue preparation for immunohistochemistry was described previously (Arnold et al., 2013) . In brief, anesthetized mice were transcardialy perfused with phosphate buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in phosphate buffer for fixation. L5 roots of 3~5 animals per genotype and age point were collected and incubated in 2% osmium tetroxide in 0.05 M cacodylate buffer. The roots were subsequently washed, dehydrated and embedded in Epon (Electron Microscopy Sciences) for sectioning. 1 mm-thick cross sections were stained with 1% toluidine blue for 30 s. Both motor and sensory axons from L5 roots were quantified as described (Arnold et al., 2013) .
Brains and spinal cords were post-fixed in 4% PFA for 2 hr, cryoprotected in 30% sucrose for over 24 hr and embedded in Tissue-Tek. For immunohistochemistry cryosections (30 mm) of fixed spinal cord and brain were rinsed in PBS, incubated in a blocking solution containing PBS, 0.5% Tween-20, 1.5% BSA for 1 hr at room temperature and transferred for an overnight incubation at room temperature in PBS, 0.3% Triton-X100 supplemented with the following primary antibodies: mouse anti-HA (Covance) at 1:5,000, anti-p62/SQSTMQ (Enzo) at 1:500, goat anti-ChAT (Chemicon) at 1:300, rabbit anti-GFAP (Dako) at 1:1000 and mouse anti-Iba1 at 1:1000. Primary antibodies were washed with PBS and then detected using donkey anti-rabbit Cy3, anti-mouse Cy3, anti-goat Cy3 (1:500) coupled secondary antibodies (Jackson ImmunoResearch). The secondary antibodies were washed with PBS and the spinal cord sections were either directly mounted or further incubated with a monoclonal antibody against neuronal nuclei marker, NeuN-Alexa488 (1:1,000, Chemicon) for 1.5 hr at room temperature. The sections were washed with PBS and mounted. Analysis was performed on a Nikon Eclipse laser scanning confocal microscope.
All lumbar spinal cord choline acetyl-transferase (ChAT) positive motor neurons were counted in the ventral horn of at least 25 sections per animal (in three mice per genotype). The total number of motor neurons counted was then divided by the number of sections.
Evaluation of muscle innervation at the neuromuscular junction (NMJ) was performed by immunohistochemistry on gastrocnemius. Floating sections (40 mm) were incubated in a blocking solution containing PBS, 0.5% Tween-20, 1.5% BSA for 4 hr at room temperature and then in PBS, 0.3% Triton-X100 overnight at room temperature with the polyclonal rabbit anti-synaptophysin antibody at 1:50 (Invitrogen). The sections were washed with PBS and then incubated first with donkey anti-rabbit Cy3 (Jackson ImmunoResearch) and a-Bungarotoxin-Alexa488 (Invitrogen) at 1:500 for 1 hr at room temperature and then with FluoroMyelin red (Invitrogen) at 1:300 for 30 min. The sections were further washed with PBS and mounted. Analysis was performed on a Nikon Eclipse laser scanning confocal microscope. A total of approximately 1000 neuromuscular junctions were counted from at least 10 sections of gastrocnemius. Individual NMJs were considered as innervated when colocalization between synaptophysin and a-Bungarotoxin staining was over 20%.
RNA-seq library preparation and sequencing, and bioinformatics analysis Abundance quantification and differential expression calling RNA quality was measured using the Agilent Bioanalyzer system. Samples with RIN (RNA integrity numbers) larger than 8.0 were used for RNA library preparation. Multiplex strand specific RNA-seq libraries were prepared from 30-day-old mouse spinal cord RNA and ASO-treated mouse spinal cord RNA using Illumina TruSeq RNA Sample Prep Kit and libraries were sequenced using Illumina HiSeq 4000 single-ended 50 bp sequencing. Read quantification was performed with Kallisto (0.44.0) (Bray et al., 2016) with parameters -b 50 -single -l 200 s 20 using ENSEMBL cDNA transcripts (release 91). Downstream differential gene expression calling was performed using Sleuth (0.28.1) (Pimentel et al., 2017) . Quantified genes from each sample were annotated with a condition tag corresponding to the sample genotype. For each gene, Wald testing was performed on the condition parameter to obtain their respective FDR-corrected p-values. Significance for each gene was then established under a cutoff of FDR < 0.1.
Diagnostic plot generation
Diagnostic plots (MA, Principal Components Analysis) were generated using the R statistical language's ggplot2 package. Expression data matrices were log-scaled before treatment with ComBat (Leek et al., 2012) , to correct batch effect stemming from the different sequencing experiments. Principal Components analysis was then performed on the batch-corrected gene Transcripts Per Million (TPM) values generated from Kallisto-sleuth gene expression quantifications. The expression data matrices from the PCA where also used for hierarchical clustering and heatmap generation. From this, a subset corresponding to the top 2500 genes by ordered by PCA loading values across the first five principal components was derived. This sub-matrix was then Z-scaled and centered before biclustering and rendering with the superheat R library (Barter and Yu, 2018) .
Visualization of read coverage
Raw read data were mapped against the ENSEMBL mouse genome and associated annotations (release 91) using the STAR aligner package (2.4.2a) with parameters: sjdbOverhang = 49. Read coverage of the various datasets was calculated using bedtools genomecov (2.17.0, -bg -split) using the GViz genomic data visualization toolkit (Harmston et al., 2015) (1.20.0).
Gene ontology analysis
Selected FDR ordered gene sets were isolated from the Cnp-heterozygous FUS WT vs homozygous FUS WT dataset. The genes were then subjected to gene ontology enrichment using the Cytoscape package ClueGO (Bindea et al., 2009 ) (2.3.0) with parameters ontology = Biological Process (GO_BiologicalProcess-GOA_23.02.2017_10h01), GO term fusion = True, GOLevels= (Gao et al., 2017; Van Deerlin et al., 2008) . The resultant network was visualized in Cytoscape (Smoot et al., 2011 ) (3.5.0) under a Benjamini-Hochberg FDR corrected p<0.05 cutoff using the included organic layout. Clusters of interest for downstream analysis were then identified from the network manually.
Cluster Gene Pathway Projection
Pathway projection of the GO-term cluster associated genes was performed as follows: For each selected cluster, we derived the set of all genes associated with all GO terms contained by the cluster. We then filtered this cluster gene set, removing all genes which were not differentially expressed in the non-transgenic vs heterozygous FUS WT analysis. The resultant gene list was then annotated with their respective foldchanges and submitted to the Reactome analyzer service for pathway enrichment. The resultant projection was then visualized using the Reactome pathway browser.
Proportional expression analysis
OE and KD gene datasets were joined on their associated Ensembl gene ID. The resultant combined table was then subset into two subtables: The 'insignificant' subset was filtered for genes with FDR values above our specified cutoff (FDR > 0.01) in either OE or KD datasets. The other 'significant' table was created similarly but was instead constrained to genes with FDRs below the cutoff value in both datasets. For each table, oppositely and similarly expressed genes were enumerated and the proportional distribution derived. A binomial test to determine a proportional shift was then performed, comparing the data against the null model (p(Opp)=0.5; p(Sim)=0.5). RNA-seq data have been deposited in NCBI's Gene Expression Omnibus with the GEO series accession number GSE125125.
Animal behavior and electrophysiology Resting electromyographic (EMG) recording
Animals were anesthetized with 2.5% isoflurane and the left hind limb shaved. To record EMG, two 30G platinum transcutaneous needle electrodes (Grass Technologies, An Astro-Med, Inc., West Warwick, Ri) were placed into the gastrocnemius muscle (distance between recording electrodes~1 cm). Electrodes were connected to an active headstage (3110W Headstage, Warner Instruments LLS), recorded signal amplified using DP-311 differential amplifier (Warner Instruments LLS) and digitalized by the PowerLab 8/30 data acquisition system (AD Instruments, Inc., Colorado Springs, CO). Recorded signal was sampled at 20 kHz and stored in PC for analysis.
Gait analysis
The footprint test was used to analyze the gait of the transgenic mice. The front and hind paws were coated with yellow and black non-toxic paints, respectively. The animals were then placed onto a 60 cm long, 10 cm wide runway with a fresh sheet of paper placed on the floor of the runway for each run. Each mouse had three runs and the runs were averaged. The center of each paw print was identified manually and the distances were measured as described.
Autophagy assay Expression constructs
The constructs used in this study were PCR-cloned into the pEBFP2 expressing vector (addgene #14893), at the Nhe I and Age I sites using the following primers: 5' forward: ctaggctagcgccaccatggcctcaaacgattatac; 3' reverse: ctagaccggtggatacggcctctccctgcgat. The BFP was fused in frame to the C-terminus of the respective FUS wild type construct or its mutants (R514G and R521C). The pDest-mCherry-EGFP-hLC3b (Addgene# 22418) construct was supplied Dr. Paul Taylor, and the mCherry-GFP-LC3 vector was obtained from Dr. Terje Johansen.
Cell culture studies
Neuro2a mouse neuroblastoma cell line was purchased from ATCC (ATCC CCL-131). Cells are fully tested for sterility from mycoplasma contamination prior to distribution by ATCC. Mycoplasma was tested quarterly and was negative. The species is also confirmed and authenticated by the Cytochrome oxidase 1 (CO1) barcode assay. Neuro2a cells were plated in a 24 well dish in DMEM media in the presence of 10% FBS, and transfected following the manufacturer's protocol. The media was changed to media without antibiotics, and 10 hr later the transfected cells were cultured in either complete media (CM) or nutrient limited media (NLM) for 8 hr. For autophagic induction studies, Neuro2A cells were fixed with 4% paraformaldehyde (PFA) for 21 min on ice, washed with PBS, and then mounted on Fluoromount G (Electron Microscopy Sciences). For p62 studies, transfected and treated cells were fixed with 4% PFA as described above, permeabilized with 0.20% Triton X-100 for 5 min on ice, and them immediately blocked with 5% BSA and goat serum for 1 hr. Cells were then incubated overnight in BFP (Abcam #32791, diluted to 1:400 in blocking serum) and p62 antibody (Enzo # BML-PW9860, diluted to 1:500 in blocking serum). The next day the primary antibody was removed and the cells were washed with PBS followed by 45 min incubation with goat anti-mouse Alexa 350 (Invitrogen, Cat#A21049, diluted to 1:100 in blocking serum) and goat anti-rabbit Alexa 594 (Invitrogen, A11037, diluted to 1:100 in blocking serum). Then the cells were stained with Syto13, washed in PBS, and mounted on Fluoromount G on glass slides.
Autophagy assay and imaging
Cell counting was performed on a Nikon eclipse 80i microscope and >100 cells were counted for each experiment. Cells were scored as positive for autophagy induction when more than seven puncta were present. To determine the autophagic flux, Neuro2A cells co-transfected with mCherry-GFP-LC3 and BFP or FUS-BFP and imaged using a Zeiss 780 confocal microscope, and >40 cells were imaged per experiment. Autophagosomes (yellow/yellow green puncta) and autolysosomes (red puncta) were counted for each cell, and the percentage of autophagosomes or autolysosomes calculated out of total puncta/cell. For p62 analysis, 10-30 images were obtained to visualize at least 60 transfected cells/experiment on a Ziess 780 confocal microscope. Cells with more than seven p62 puncta were scored as positive.
Statistical analysis
We performed unpaired two-tailed t-test (non-parametric, Student's t test) or one-way ANOVA (using Bonferroni's multiple comparison test). All experiments were repeated at least three times. Data availability RNA-seq data have been deposited in NCBI's Gene Expression Omnibus with the GEO series accession number GSE125125.
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